GrayBug Secures Worldwide Rights to Develop Proprietary Ophthalmic Drug Delivery Platforms


GrayBug raises $1mm from investors and is awarded a $200k grant to support research

Baltimore, MD – April 11, 2012 – GrayBug LLC announced today they have raised over $1 million in equity from investors and have successfully obtained the worldwide right to new technologies invented by GrayBug LLC co-founders Justin Hanes, Peter Campochiaro, and Peter McDonnell through a licensing deal with the John Hopkins University.

GrayBug was also awarded a $200k grant from The Maryland Biotechnology Center through their Biotech Development Program to support development of the company’s lead product targeting Age Related Macular Degeneration (AMD).

GrayBug is a biotechnology company that is developing proprietary controlled release technologies for pharmaceutical indications. The company’s lead product is a polymer-drug biomolecular conjugate for the treatment of neovascular diseases of the eye. GrayBug’s proprietary platform technology allows sustained drug delivery into various compartments of the eye while minimizing inflammation common with current controlled release technologies applied to the eye.

Related News

Press release

Graybug Vision Appoints Parisa Zamiri, Physician-Scientist with Deep Expertise in Ophthalmology, as Chief Medical Officer

REDWOOD CITY, Calif., May 18, 2020 – Graybug Vision, Inc., a clinical stage biopharmaceutical company focused on developing transformative medicines to treat vision-threatening diseases of the retina and optic nerve, appoints Parisa Zamiri M.D., Ph.D. Read more…

Press release

Nature Communications Highlights Research by Scientists at Graybug Vision and Johns Hopkins University on Sustained Treatment of Retinal Diseases

REDWOOD CITY, Calif., April 21, 2020 – Graybug Vision, Inc., a clinical stage biopharmaceutical company focused on developing transformative medicines to treat vision-threatening diseases of the retina and optic nerve, announces that a recent publication Read more…

Press release

Joint Statement on Retina Clinical Trials and COVID-19

To our Colleagues in the Retina Clinical Trials Community: We all take the health and safety of patients, healthcare providers, and our local communities very seriously, and the ongoing pandemic is challenging healthcare delivery and Read more…